Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Haas

Showing results (511-520 of 554) with videos related to

Pageof 56
Sort By:
Cell Metabolism|July 8, 2014
Akt-dependent metabolic reprogramming regulates tumor cell histone acetylationJoyce V Lee, Alessandro Carrer, Supriya Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid TumorsClinton Yam, Xiaowei Xu, Michael A Davies, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaToni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191Bonnie Ky, Tao Liu, Kenneth B Margulies, et al.
Nature Ecology & Evolution|August 25, 2025
Origin and evolutionary trajectories of brown algal sex chromosomesJosué Barrera-Redondo, Agnieszka P Lipinska, Pengfei Liu, et al.
NPJ Vaccines|June 8, 2024
Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trialJaimie Z Shing, Carolina Porras, Maísa Pinheiro, et al.
Plos One|October 5, 2023
Assessing the associations between known genetic variants and substance use in people with HIV in the United StatesCameron B Haas, Kristina M Jordahl, Robin M Nance, et al.
Pageof 56

Showing results (511-520 of 554) with videos related to

Sort By:
Pageof 56
Cell Metabolism|July 8, 2014
Akt-dependent metabolic reprogramming regulates tumor cell histone acetylationJoyce V Lee, Alessandro Carrer, Supriya Shah, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 21, 2017
A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid TumorsClinton Yam, Xiaowei Xu, Michael A Davies, et al.
European Urology|March 18, 2014
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohortEthan Basch, Karen A Autio, Matthew R Smith, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell CarcinomaRobert J Motzer, Naomi B Haas, Frede Donskov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinomaToni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|June 2, 2026
Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate CancerTaylor B Crawford, Maliha Tayeb, Emanuel Barrett, et al.
Hypertension (Dallas, Tex. : 1979)|May 20, 2026
Cluster Randomized Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191Bonnie Ky, Tao Liu, Kenneth B Margulies, et al.
Nature Ecology & Evolution|August 25, 2025
Origin and evolutionary trajectories of brown algal sex chromosomesJosué Barrera-Redondo, Agnieszka P Lipinska, Pengfei Liu, et al.
NPJ Vaccines|June 8, 2024
Differential long-term bivalent HPV vaccine cross-protection by variants in the Costa Rica HPV vaccine trialJaimie Z Shing, Carolina Porras, Maísa Pinheiro, et al.
Plos One|October 5, 2023
Assessing the associations between known genetic variants and substance use in people with HIV in the United StatesCameron B Haas, Kristina M Jordahl, Robin M Nance, et al.
Pageof 56